H. Bentzen

Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur

E. Kimby, J. Delabie, M. Karjalainen‐Lindsberg, 2012, British journal of haematology.

A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma

P. Hokland, C. Nyvold, H. Bentzen, 2012, European journal of haematology.

SOX11 as a minimal residual disease marker for Mantle cell lymphoma.

J. Bødker, A. T. Simonsen, C. Nyvold, 2014, Leukemia research.

(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)

J. Delabie, M. Karjalainen‐Lindsberg, M. Ehinger, 2009 .

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

K. Grønbæk, M. Jerkeman, U. Fagerli, 2020, HemaSphere.

Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma.

E. Kjeldsen, M. Thomassen, N. Abildgaard, 2020, Experimental hematology.

15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

E. Kimby, J. Delabie, C. Workman, 2016, British journal of haematology.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

E. Kimby, J. Delabie, K. Grønbæk, 2014, Blood.

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

E. Kimby, J. Delabie, K. Grønbæk, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nordic MCL 3 study : 90 Y-ibritumomab-tiuxetan added to BEAM / C in non-CR patients before transplant in mantle cell lymphoma

E. Kimby, J. Delabie, K. Grønbæk, 2014 .

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.

F. d'Amore, S. Leppä, T. Plesner, 2018, Blood advances.

Differential expression levels and methylation status of ROBO1 in mantle cell lymphoma and chronic lymphocytic leukaemia

P. Hokland, A. Aggerholm, C. Nyvold, 2017, International journal of laboratory hematology.